Editorial: gut selective immunosuppression-is it a double edged sword? Authors' reply.

Abstract

The Editorial on the safety of vedolizumab by Sheridan and Doherty in response to our safety review is thoughtful and well balanced, but there are post-marketing data on malignancy after >25000 patient-years of experience with vedolizumab that they do not mentio